Table 1

Baseline demographic and clinical characteristics of patients with PAH-CHD in Pulmonary Arterial hyperTENsion sGC-stimulator Trial-1

CharacteristicPlacebo
(n=12)
Riociguat 2.5 mg–maximum (n=15)Riociguat 1.5 mg–maximum (n=8)Total (n=35)
Female, n (%)10 (83)13 (87)6 (75)29 (83)
Age, mean±SD (years)40±1635±1441±1538±15
Body mass index, mean±SD (kg/m2)24±321±224±523±4
CHD subtype, n (%)
 Corrected atrial septal defect6 (50)5 (33)3 (38)14 (40)
 Corrected ventricular septal defect3 (25)7 (47)2 (25)12 (34)
 Corrected persistent ductus arteriosus3 (25)2 (13)3 (38)8 (23)
 Missing01 (7)01 (3)
WHO FC II/III, %58/4267/3350/5060/40
Time since last corrective surgery, mean±SD (years)16±1219±1413±1117±13
In receipt of additional PAH treatment at baseline, n (%)
 No8 (67)8 (53)4 (50)20 (57)
 Yes4 (33)7 (47)4 (50)15 (43)
  ERA3 (25)5 (33)4 (50)12 (34)
  Prostanoid1 (8)2 (13)03 (9)
6MWD, mean±SD (m)360±59369±78391±59371±11
  • 6MWD, 6-min walking distance; CHD, congenital heart disease; ERA, endothelin receptor antagonist; PAH, pulmonary arterial hypertension; WHO FC, WHO functional class.